2022-03-21T15:22:24-05:00 2021-06-30 860683059 BEACHFLEISCHMAN PLLC 1985 E RIVER ROAD SUITE 201 TUCSON AZ 85718 990 2020-07-01 201991334 CRITICAL PATH INSTITUTE CRIT 5205473440 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 KEVIN B PERKINS CFO 5205473440 2022-03-18 1 KEVIN PERKINS 999009999 KELLY L MELTZER CPA P00633511 5203214600 2022-03-18 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z KRISTEN L SWINGLE 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 24427097 0 X C-PATH.ORG X 2004 AZ INTERNATIONAL COLLABORATIONS AND NOVEL TOOLS TO ENABLE FASTER DEVELOPMENT OF SAFER MEDICAL PRODUCTS 14 14 131 14 0 0 12978641 17810315 5292779 6610023 156753 5817 36141 942 18464314 24427097 2697926 3294397 0 0 10893350 14630286 0 0 0 3961324 5080822 17552600 23005505 911714 1421592 16657850 18494765 7630738 8046061 9027112 10448704 X THE CRITICAL PATH INSTITUTE IS A CATALYST IN THE DEVELOPMENT OF NEW APPROACHES THAT ADVANCE MEDICAL INNOVATION AND REGULATORY SCIENCE. THIS IS ACHIEVED BY LEADING TEAMS THAT SHARE DATA, KNOWLEDGE AND EXPERTISE RESULTING IN SOUND, CONSENSUS BASED SCIENCE. 0 0 5403459 1881984 1216 THE RARE DISEASE CURES ACCELERATOR-DATA AND ANALYTICS PLATFORM (RDCA-DAP) - SEE SCHEDULE O 1042906 200992 0 THE RARE DISEASE CLINICAL OUTCOME ASSESSMENT CONSORTIUM (RD-COAC) - SEE SCHEDULE O 898634 12500 0 THE HUNTINGTON'S DISEASE REGULATORY SCIENCE CONSORTIUM (HD-RSC) - SEE SCHEDULE O 9330377 1198921 6609749 CRITICAL PATH INSTITUTE ALSO EXECUTES OTHER PROJECTS AND CONSORTIA IN AREAS INCLUDING THERAPEUTICS FOR THE ATAXIAS, POLYCYSTIC KIDNEY DISORDER, ALZHEIMER'S DISEASE, CURE DRUG REPURPOSING, PARKINSON'S, TB, SICKLE CELL, TYPE ONE DIABETES, ALZHEIMER'S DISEASE, DUCHENNE MUSCULAR DYSTROPHY, MODEL INFORMED DRUG DEVELOPMENT, REAL-WORLD EVIDENCE, PATIENT-REPORTED OUTCOME, ELECTRONIC CLINICAL OUTCOME ASSESSMENT, TRANSPLANT THERAPEUTICS, PREDICTIVE SAFETY TESTING, AND OTHERS. 9330377 1198921 6609749 16675376 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 1 0 0 1 19 0 1 131 1 0 1 EI 0 0 0 0 0 0 0 0 0 0 X 14 14 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X KEVIN B PERKINS CFO 5206478382 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 DR JOSEPH SCHEEREN PRESIDENT & CEO THROUGH 03/19/2021 40.00 X X 361951 0 34251 MS KRISTEN SWINGLE CHIEF OPERATING OFFICER & TREASURER 40.00 X 234391 0 30125 DR KLAUS ROMERO CHIEF SCIENCE OFFICER 40.00 X 213166 0 29953 DR JOHN MICHAEL SAUER PROGRAM OFFICER 40.00 X 204323 0 34359 DR STEPHEN COONS PROGRAM OFFICER 40.00 X 192261 0 28770 DR INISH O'DOHERTY EXECUTIVE DIRECTOR 40.00 X 192570 0 16607 DR DIANE STEPHENSON EXECUTIVE DIRECTOR 40.00 X 179844 0 27673 MS SONYA EREMENCO EXECUTIVE DIRECTOR 40.00 X 179844 0 26733 DR RICHARD LIWSKI CHIEF TECHNOLOGY OFFICER 40.00 X 184513 0 19911 DR SUDHIR SIVAKUMARAN VICE PRESIDENT/EXECUTIVE DIRECTOR 40.00 X 171295 0 23289 DR JEFF BARRETT SENIOR VICE PRESIDENT 40.00 X 142792 0 3596 MR LEWIS BARBIERI CORPORATE SECRETARY 40.00 X 123433 0 21603 MS MARA G ASPINALL BOARD MEMBER 1.00 X 0 0 0 DR ROBERT M CALIFF BOARD MEMBER 1.00 X 0 0 0 MS KAY HOLCOMBE BOARD MEMBER 1.00 X 0 0 0 MR PETER BARTON HUTT BOARD MEMBER 1.00 X 0 0 0 MR JEFFREY JACOB BOARD MEMBER 1.00 X 0 0 0 MR SHAUN A KIRKPATRICK BOARD MEMBER 1.00 X 0 0 0 MR ALAN G LEVIN BOARD MEMBER 1.00 X 0 0 0 MR JAMES W NEWMAN BOARD MEMBER 1.00 X 0 0 0 DR PAULA J OLSIEWSKI BOARD MEMBER 1.00 X 0 0 0 DR TOMAS SALMONSON BOARD MEMBER 1.00 X 0 0 0 DR ALASTAIR JJ WOOD BOARD MEMBER 1.00 X 0 0 0 DR TIMOTHY R FRANSON CHAIRMAN 1.00 X X 0 0 0 MR M WAINWRIGHT FISHBURN JR VICE CHAIRMAN 1.00 X X 0 0 0 2380383 0 296870 33 0 1 0 ARIDHIA INFORMATICS LIMITED 1345 GOVAN ROAD GLASGOW G51 4TF UK IT SERVICES 609719 ROCHE DIAGNOSTICS OPERATIONS INC 9115 HAGUE ROAD INDIANAPOLIS IN 46250 RESEARCH SERVICES 245035 LOTOS NILE PO BOX 90245 NASHVILLE TN 37209 PUBLIC RELATIONS 238936 3 13307065 4503250 17810315 RESEARCH SUPPORT FEES 541700 6417597 6417597 OTHER REVENUE 900099 192426 192426 6610023 5817 5817 EARNINGS FROM SUBSIDIARY 900099 942 942 942 24427097 6610965 0 5817 2981277 2981277 313120 313120 1691914 1203897 488017 10530391 7356393 3173998 691272 483087 208185 879116 614706 264410 837593 586509 251084 36145 2045 34100 56540 56540 2099222 1626655 472567 308491 65562 242929 215873 19756 196117 1276724 761326 515398 593573 423574 169999 205373 176305 29068 35674 4806 30868 88237 88237 MISCELLANEOUS 112674 29948 82726 DUES AND SUBSCRIPTIONS 52296 26410 25886 23005505 16675376 6330129 0 8304830 2563917 2281093 13473971 1581850 1572024 993569 365250 42677 38270 478006 387606 83834 90400 3143650 249017 226347 141916 16657850 18494765 1209284 1587126 6353841 6375005 67613 83930 7630738 8046061 X 9027112 10448704 9027112 10448704 16657850 18494765 1421592 0 X 0 1 X 1 1 1 X 10085049 10019550 10698823 12978641 17810315 61592378 10085049 10019550 10698823 12978641 17810315 61592378 17105176 44487202 48471 83667 215046 156753 5817 509754 62102132 28520142 0.71640 0.59330 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 23005505 23005505 1000000 250000 0 0 875586 918648 1000000 1000000 3794234 5691351 60816 60816 218897 229662 250000 250000 948559 1422839 PART II-A, LINE 1B C-PATH DOES NOT LOBBY FOR OR AGAINST ANY SPECIFIC LEGISLATION. C-PATH DOES EXPEND A MODEST AMOUNT OF TIME AND MONEY TO EDUCATE LEGISLATORS AND THEIR STAFF IN THE AREA OF DRUG DEVELOPMENT. 42014 42014 0 136750 125178 11572 299242 220414 78828 90400 DEFERRED RENT 83930 83930 X PART X, LINE 2: FINANCIAL STATEMENT FIN 48 (ASC 740) FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION UNDER INTERNAL REVENUE CODE SECTION 509(A)(1). INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME (UBTI). 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION CLINICAL RESEARCH 302380 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 INVESTMENT 5392 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION CLINICAL RESEARCH 10740 0 0 0 0 0 0 318512 0 318512 EUROPE (INCLUDING ICELAND & GREENLAND) SUBAWARD 14008 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) REGULATORY FEES 15977 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) T&M WORK 33799 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) CONSULTANT 5832 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) CLINICAL RESEARCH 213679 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) CONSULTANT 19085 WIRE TRANSFER EAST ASIA AND THE PACIFIC CLINICAL RESEARCH 10740 WIRE TRANSFER 4 3 0 0 1 0 0 0 PART I, LINE 2: CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. PART III ACCOUNTING METHOD: 1 NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) DEPT 5430 PO BOX 4110 WOBURN MA 01888 133223946 501(C)(3) 2069222 SUBAWARD EDETEK INC 101 COLLEGE RD EAST 2NFD FLOOR PRINCETON NJ 08540 271480018 167500 SUBAWARD EVIDERA INC PO BOX 758641 BALTIMORE MD 21275 541759539 161003 SUBAWARD & RESEARCH MAYO CLINIC PO BOX 1658 MINNEAPOLIS MN 55480 416011702 501(C)(3) 117730 SUBAWARD JAEB CENTER FOR HEALTH RESEARCH 15310 AMBERLY DRIVE SUITE 350 TAMPA FL 33647 593187624 501(C)(3) 83694 SUBAWARD ADELPHI VALUES 290 CONGRESS STREET BOSTON MA 02210 043445547 50300 SUBAWARD TUFTS MEDICAL CENTER INC 800 WASHINGTON STREET RF BOX 453 BOSTON MA 02111 043400617 501(C)(3) 27869 SUBAWARD MYRIAD RBM INC 3300 DUVAL ROAD SUITE 110 AUSTIN TX 78759 223860791 26510 SUBAWARD INSTITUTE FOR ADVANCED CLINICAL TRIALS FOR CHILDREN 9211 CORPORATE BLVD SUITE 260 ROCKVILLE MD 20850 812076517 501(C)(3) 11650 SUBAWARD NORTHWESTERN UNIVERSITY 625 MICHIGAN AVENUE 27TH FLOOR SUITE 2100 CHICAGO IL 60611 362167817 501(C)(3) 265799 SUBAWARD 6 4 PART I, LINE 2: CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. X X X X 0 0 0 0 0 0 0 1 0 DR JOSEPH SCHEEREN PRESIDENT & CEO THROUGH 03/19/2021 361951 0 0 0 0 0 20989 0 13262 0 396202 0 0 0 MS KRISTEN SWINGLE CHIEF OPERATING OFFICER & TREASURER 234391 0 0 0 0 0 12702 0 17423 0 264516 0 0 0 DR KLAUS ROMERO CHIEF SCIENCE OFFICER 213166 0 0 0 0 0 16763 0 13190 0 243119 0 0 0 DR JOHN MICHAEL SAUER PROGRAM OFFICER 204323 0 0 0 0 0 16973 0 17386 0 238682 0 0 0 DR STEPHEN COONS PROGRAM OFFICER 192261 0 0 0 0 0 15614 0 13156 0 221031 0 0 0 DR INISH O'DOHERTY EXECUTIVE DIRECTOR 192570 0 0 0 0 0 15360 0 1247 0 209177 0 0 0 DR DIANE STEPHENSON EXECUTIVE DIRECTOR 179844 0 0 0 0 0 14722 0 12951 0 207517 0 0 0 MS SONYA EREMENCO EXECUTIVE DIRECTOR 179844 0 0 0 0 0 13863 0 12870 0 206577 0 0 0 DR RICHARD LIWSKI CHIEF TECHNOLOGY OFFICER 184513 0 0 0 0 0 12161 0 7750 0 204424 0 0 0 DR SUDHIR SIVAKUMARAN VICE PRESIDENT/EXECUTIVE DIRECTOR 171295 0 0 0 0 0 13982 0 9307 0 194584 0 0 0 PART I, LINE 7 CRITICAL PATH AWARDS VARIABLE COMPENSATION BASED ON PERFORMANCE AND WITH GUIDANCE FROM THE COMPENSATION COMMITTEE. AMY PORTER SPOUSE OF JOHN-MICHAEL SAUER, KEY EMPLOYEE 106800 CONSULTING SERVICES - SCIENTIFIC/TECHNICAL WRITING 0 FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICES: THE RARE DISEASE CURES ACCELERATOR-DATA AND ANALYTICS PLATFORM (RDCA-DAP) IS AN FDA-FUNDED INITIATIVE THAT PROVIDES A CENTRALIZED AND STANDARDIZED INFRASTRUCTURE TO SUPPORT AND ACCELERATE RARE DISEASE CHARACTERIZATION, WITH THE GOAL OF ACCELERATING THERAPY DEVELOPMENT ACROSS RARE DISEASES. THIS PLATFORM IS MADE POSSIBLE THROUGH A COLLABORATIVE GRANT FROM THE FDA AND IN PARTNERSHIP WITH THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD). RDCA-DAP PROMOTES THE SHARING OF EXISTING PATIENT-LEVEL DATA AND ENCOURAGES THE STANDARDIZATION OF NEW DATA COLLECTION. BY INTEGRATING SUCH DATA IN A REGULATORY-GRADE FORMAT SUITABLE FOR ANALYTICS, RDCA- DAP ACCELERATES THE UNDERSTANDING OF DISEASE PROGRESSION (INCLUDING SOURCES OF VARIABILITY TO OPTIMIZE THE CHARACTERIZATION OF SUBPOPULATIONS), CLINICAL OUTCOME MEASURES AND BIOMARKERS, AND FACILITATES THE DEVELOPMENT OF MATHEMATICAL MODELS OF DISEASE AND INNOVATIVE CLINICAL TRIAL DESIGNS. RDCA-DAP IS POSITIONED TO GENERATE SOLUTIONS TO DRUG DEVELOPMENT BOTTLENECKS. ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) SIGNED 13 DATA CONTRIBUTION AGREEMENTS AND IS CURRENTLY NEGOTIATING AGREEMENTS WITH 21 ADDITIONAL GROUPS. AS OF JUNE 30, 2021, THE PLATFORM INCLUDES OVER 60 RARE DISEASE DATASETS IN-HOUSE FROM 18 DISEASE AREAS; (2) SIGNED MEMORANDA OF UNDERSTANDING WITH FIVE RARE DISEASES DATA COMPANIES (U.S. AND INTERNATIONAL) TO FRAME COLLABORATIONS THAT WILL HELP INCREASE THE POOL OF DATA AVAILABLE AND THE PLATFORM FUNCTIONALITY, VISIBILITY AND VALUE TO DRUG DEVELOPMENT; (3) COMPLETED TWO PROTOTYPE PROJECTS TO DEMONSTRATE THE VALUE OF THE PLATFORM BY DEMONSTRATING THE ABILITY TO INTEGRATE DATA ACROSS RELATED DISEASES (POLYCYSTIC KIDNEY DISEASE AND KIDNEY TRANSPLANT) AND DEVELOPMENT OF A DISEASE PROGRESSION MODEL FOR POLYCYSTIC KIDNEY DISEASE. RDCA-DAP ALSO ADVANCED PILOT ANALYTICAL WORK FOR DISEASE MODELING AND DATA-DRIVEN SOLUTIONS FOR FREIDREICH'S ATAXIA IN COLLABORATION WITH FARA; AND, (4) HELPED ADVANCE THE PLATFORM DEVELOPMENT INCLUDING BETA-TESTING OF THE PLATFORM'S FIRST ITERATION (WITH TESTERS FROM ACADEMIC, DATA SCIENCE/ QUANTITATIVE MODELING AND PLATFORM/PATIENT GROUP SEGMENTS OF OUR END USER BASE) AND ONGOING BUILDING OF AN APPLICATION PROGRAMMING INTERFACE WITH NORD'S IAMRARE REGISTRY PLATFORM. FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICES: THE GOAL OF THE RARE DISEASE CLINICAL OUTCOME ASSESSMENT CONSORTIUM (RD-COAC) WILL BE TO OPTIMIZE COA SELECTION DURING MEDICAL PRODUCT DEVELOPMENT FOR RARE DISEASES. WORK TOWARDS ESTABLISHMENT OF THIS CONSORTIUM BEGAN WITH FDA FUNDING IN 2019 AS THE RARE DISEASE SUBCOMMITTEE. THE RARE DISEASE SUBCOMMITTEE WAS ESTABLISHED WITHIN THE PRO CONSORTIUM (PROC) AND INCLUDES REPRESENTATIVES FROM FDA, THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD), THE NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCE (NCATS), THE PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (PCORI), BIOPHARMACEUTICAL FIRMS, AS WELL AS THREE CLINICAL EXPERTS. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) COMPLETED THE LANDSCAPE ANALYSES FOR THE DAILY FUNCTION SUBDOMAINS OF SELF-CARE, GROSS MOTOR FUNCTION, FINE MOTOR FUNCTION, AND COMMUNICATION; (2) COMPLETED THE GAP ANALYSES OF 68 COAS FOR THE DAILY FUNCTION SUBDOMAINS OF SELF-CARE, GROSS MOTOR FUNCTION, AND FINE MOTOR FUNCTION; (3) CONDUCTED A VIRTUAL WORKSHOP TITLED COVID-19 MITIGATION STRATEGIES IN PEDIATRIC RARE DISEASE CLINICAL TRIALS; 4) COMPLETED AN ONLINE SURVEY OF NORD'S IAMRARE REGISTRY PARTNERS; AND (5) EXPANDED MEMBERSHIP THROUGH AGREEMENTS WITH NEW INDUSTRY AND NON-PROFIT MEMBERS. FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICES: THE GOAL OF THE HUNTINGTON'S DISEASE REGULATORY SCIENCE CONSORTIUM (HD-RSC) IS TO BRING TOGETHER PARTICIPANTS FROM ACROSS THE GLOBAL HUNTINGTON'S DISEASE (HD) COMMUNITY WITH THE GOAL TO CREATE AND ADVANCE DRUG DEVELOPMENT TOOLS FOR REGULATORY ENDORSEMENT AND ACCELERATE THE OVERALL DEVELOPMENT OF NOVEL THERAPEUTICS FOR HD. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) SUBMISSION OF A LETTER OF INTENT, AS PART OF A LARGER BRIEFING PACKAGE, TO FDA UNDER THE FIT-FOR-PURPOSE INITIATIVE; (2) COMPLETION OF TWO MANUSCRIPTS ON IMAGING BIOMARKERS FOR SUBMISSION TO FRONTIERS IN NEUROSCIENCE; (3) CREATION OF THE HD INTEGRATED STAGING SYSTEM FOR CLINICAL USE BY THE REGULATORY SCIENCE FORUM WORKGROUP AND A COMPANION MANUSCRIPT TO BE SUBMITTED TO THE LANCET NEUROLOGY; (4) EXPANSION OF THE HD DATABASE, CURRENTLY REPRESENTING 28,300 PATIENTS. FORM 990, PART VI, SECTION A, LINE 2 PETER HUTT AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. WAIN FISHBURN AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. JEFF JACOB AND SHAUN KIRKPATRICK HAVE A BUSINESS RELATIONSHIP. TOMAS SALMONSON AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S CFO, COO, PRESIDENT/CEO, THE BOARD AUDIT, FINANCE, AND RISK COMMITTEE, AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. FORM 990, PART VI, SECTION B, LINE 12C ALL MEMBERS OF THE BOARD OF DIRECTORS AND ALL OFFICERS OF THE ORGANIZATION ARE REQUIRED TO FILL OUT A CONFLICT OF INTEREST FORM ANNUALLY. THE RESULTS ARE COMPILED AND REVIEWED BY THE BOARD'S AUDIT, FINANCE, AND RISK COMMITTEE. ANY ACTUAL OR PERCEIVED CONFLICTS THAT HAVE THE POTENTIAL TO BIAS ANY DISCUSSIONS OR DECISIONS BY THE BOARD ARE DISCUSSED BY THE BOARD. ANY DIRECTOR WITH A REAL OR POTENTIAL CONFLICT WILL RECUSE THEMSELVES FROM ANY DISCUSSION OR DECISION WHERE THE CONFLICT HAS A BEARING. FORM 990, PART VI, SECTION B, LINE 15 A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. PERIODICALLY, THE COMMITTEE REQUESTS A COMPENSATION ANALYSIS TO DETERMINE IF EMPLOYEE COMPENSATION HAS REMAINED WITHIN MARKET RANGE OR IF ADJUSTMENTS ARE REQUIRED. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. AN OVERALL SALARY PROGRAM FOR EMPLOYEES MUST BE APPROVED BY THE BOARD OF DIRECTORS COMPENSATION COMMITTEE BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/CEO. FORM 990, PART VI, SECTION C, LINE 19 ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. CRITICAL PATH INSTITUTE LTD 33 SIR JOHN ROGERSONS QUAY DUBLIN EI 2 FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY EI CRITICAL PATH INSTITUTE C 259511 1.00000 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CRITICAL PATH INSTITUTE LTD D 126551 END OF YEAR BALANCE